文献速递淋巴瘤造血干细胞移植与细胞治疗

B细胞淋巴瘤中CAR T与双特异性抗体的感染风险比较:系统评价与Meta分析

Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis.
PubMed 文献 · Blood Adv · 2025-01-01

本Meta分析纳入25项前瞻性试验共3202例B细胞非霍奇金淋巴瘤患者,比较商业化CD19 CAR T与CD3xCD20双特异性抗体的感染发生率。两者每例患者全级别感染率相似(0.44 vs 0.54,P=.18),但双特异性抗体每患者月感染率更高(0.0397 vs 0.0167,P=.0012),每患者月3级及以上感染率亦更高(0.0165 vs 0.0069,P=.0003),感染相关死亡率相似。

要点

  • 每例患者全级别感染率CAR T 0.44 vs 双特异性抗体0.54,差异无统计学意义(P=.18)。
  • 每患者月全级别感染率双特异性抗体0.0397高于CAR T 0.0167(P=.0012)。
  • 每患者月3级及以上感染率双特异性抗体0.0165高于CAR T 0.0069(P=.0003)。

核心结论

  • 研究结果提示接受双特异性抗体治疗的患者随时间推移感染负担可能增加,尤其是接受无限期治疗的患者。

研究设计与样本

  • 系统评价与Meta分析,纳入25项评估商业化CD19 CAR T与CD3xCD20双特异性抗体治疗B细胞非霍奇金淋巴瘤的前瞻性试验,共3202例患者。
  • 采用随机效应模型计算每例患者及每患者月的全级别感染、3级及以上感染和感染相关死亡的合并率。

主要发现

  • 每例患者全级别感染率CAR T 0.44 vs 双特异性抗体0.54(P=.18)。
  • 每患者月全级别感染率双特异性抗体0.0397 vs CAR T 0.0167(P=.0012)。
  • 每例患者3级及以上感染率CAR T 0.16 vs 双特异性抗体0.22(P=.08)。
  • 每患者月3级及以上感染率双特异性抗体0.0165 vs CAR T 0.0069(P=.0003)。
  • 每例患者感染相关死亡率CAR T 0.04 vs 双特异性抗体0.03(P=.26);每患者月感染相关死亡率CAR T 0.0023 vs 双特异性抗体0.0022(P=.96)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD3xCD20 bispecific antibody (BsAb) therapy and CD19-directed chimeric antigen receptor T-cell therapy (CAR T) are novel immunotherapies that have shown impressive efficacy in B-cell lymphomas, but also come with significant morbidity and mortality, including infections. This meta-analysis compares rates of infections between commercially approved CAR T and BsAb therapy in patients with B-cell non-Hodgkin lymphoma (B-NHL). We conducted a systematic review for prospective trials assessing commercially approved CAR T and BsAbs in patients with B-NHL. Twenty-five studies comprising 3202 patients were included in the analysis. We used random effects models to evaluate all-grade infections, grade 3+ infections, and infection-related mortality, calculating both pooled rates per patient and per patient-month. While CAR T and BsAbs had similar rates of all-grade infections per patient (0.44 vs 0.54; P = .18), BsAbs had a higher rate of infection per patient-month (0.0397 vs 0.0167; P = .0012). Similarly, CAR T and BsAbs had similar rates of grade 3+ infections per patient (0.16 vs 0.22; P = .08), while BsAbs had a higher rate of grade 3+ infections per patient-month (0.0165 vs 0.0069; P = .0003). CAR T and BsAb products had similar rates of infection-related mortality per patient (0.04 vs 0.03; P = .26) and per patient-month (0.0023 vs 0.0022; P = .96). Our findings point to the potential increased burden of infections over time in patients receiving BsAb therapy, particularly for patients on indefinite therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. van Besien H, Easwar N, Demetres M, et al. Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2025. PMID: 40590871. doi:10.1182/bloodadvances.2025016291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。